2. Academic Validation
  3. Preclinical data on co-delivery of temozolomide and talazoparib by fucodain-coated nanoscale metal organic frameworks for colorectal cancer chemoradiation

Preclinical data on co-delivery of temozolomide and talazoparib by fucodain-coated nanoscale metal organic frameworks for colorectal cancer chemoradiation

  • Data Brief. 2021 Sep 22:38:107394. doi: 10.1016/j.dib.2021.107394.
Allison N DuRoss 1,  Madeleine R Landry 1,  Charles R Thomas Jr 2 3,  Megan J Neufeld 1,  Conroy Sun 1 2
Affiliations

Affiliations

  • 1 Department of Pharmaceutical Sciences, Oregon State University, 2730 SW Moody Ave, Portland, OR 97201, USA.
  • 2 Department of Radiation Medicine, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA.
  • 3 Radiation Oncology, Geisel School of Medicine at Dartmouth, Norris Cotton Cancer Center, One Medical Center Drive, Lebanon, NH 03756, USA.
PMID: 34632011 DOI: 10.1016/j.dib.2021.107394
Abstract

Nanoparticle characterization and in vitro data on the effects of combined PARP inhibition and DNA damage by chemoradiation are shown. This data accompanies the research article "Fucoidan-coated nanoparticles target radiation-induced P-selectin to enhance chemoradiotherapy in murine colorectal Cancer" (DuRoss et al., 2021) Additional characterization of the physiochemical properties of nanoscale metal organic frameworks (nMOFs) comprised of hafnium and 1,4-dicarboxybenzene (Hf-BDC) loaded with temozolomide (TMZ) and talazoparib (Tal) are presented. Toxicity data of the drug-loaded nMOF coated with fucoidan (TT@Hf-BDC-Fuco) in colorectal Cancer cells, CT-26, from alamarBlue-based chemoradiation experiments are shown. Experimental methods for the nanoparticle characterization and cell-based assays of the nMOF formulation are presented.

Keywords

DNA Damage; MOF; Nanomedicine; PARP; Radiation therapy.

Figures
Products